Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 35.2% in February

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 59,700 shares, a drop of 35.2% from the February 13th total of 92,200 shares. Based on an average daily volume of 376,300 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.4% of the company’s shares are short sold.

Avenue Therapeutics Stock Up 9.7 %

Shares of ATXI stock opened at $0.85 on Friday. The stock has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.91. The firm has a market cap of $1.74 million, a price-to-earnings ratio of 0.05 and a beta of -0.29. Avenue Therapeutics has a 12 month low of $0.72 and a 12 month high of $12.75.

Institutional Trading of Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Boothbay Fund Management LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 41,089 shares of the company’s stock, valued at approximately $82,000. Boothbay Fund Management LLC owned 2.00% of Avenue Therapeutics as of its most recent SEC filing. 17.34% of the stock is owned by hedge funds and other institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.